Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 985 across all filing types
Latest filing 2018-11-20 Regulatory Filings
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The provided document text appears to be heavily encoded or corrupted, containing no readable or meaningful content related to financial reporting, regulatory announcements, or corporate filings. There are no identifiable keywords, regulatory references, fiscal period dates, or document titles that would allow classification into any specific filing category. Given the lack of discernible information and the fallback rule for documents that do not fit any category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable as a formal report or announcement.
2018-11-20 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, specifically a Definitive Additional Materials filing supplementing a Definitive Proxy Statement related to a special meeting of stockholders for a merger transaction. It includes supplemental disclosures about litigation related to the merger, amendments to the proxy statement sections, and detailed information about the solicitation of proxies. The document is not the proxy statement itself but additional materials supplementing it. The content focuses on proxy solicitation and shareholder voting matters related to the merger. Therefore, the filing type corresponds to Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a simple report publication announcement but substantive proxy solicitation material.
2018-11-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 19, 2018, by OvaScience, Inc. It discusses a supplement to a Definitive Proxy Statement related to a planned merger transaction with Millendo Therapeutics, Inc. The content includes litigation disclosures, amendments to the proxy statement, and information about the merger process and related stockholder litigation. The document is not the proxy statement itself but a current report supplementing disclosures about the merger and litigation. It is not a full annual or quarterly report, earnings release, or other financial report. It is also not a direct merger filing like a DEFM14A or SC TO-*, but rather a regulatory filing updating investors on material events related to the merger and litigation. Given the nature of the content and the form type (8-K), the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2018-11-19 English
425 Filing
Regulatory Filings
2018-11-19 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-3 filed by OvaScience, Inc. The content focuses on legal and regulatory compliance issues related to the registration statement and the underlying stock purchase agreement. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory correspondence addressing SEC comments, not a financial report or announcement of voting results, management changes, or capital updates. It is not a report publication announcement since it contains substantive responses rather than a brief notice. The document fits best under Regulatory Filings (RNS) as it is a regulatory correspondence and does not fit other specific categories.
2018-11-16 English
Regulatory Filings 2018
Regulatory Filings
2018-11-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.